Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine tartrate
Drug ID BADD_D01956
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D02558
MeSH ID D000068836
PubChem ID 6918078
TTD Drug ID D0WY5Q
NDC Product Code 60687-574; 55111-355; 62756-146; 62756-148; 62756-145; 75834-135; 51991-794; 33342-090; 49706-1826; 65862-650; 51991-795; 71209-012; 71209-015; 0904-6587; 62704-0122; 33342-092; 65862-651; 46708-066; 75834-134; 55111-354; 50379-0012; 33342-089; 46708-873; 71209-014; 65862-649; 65862-648; 62756-147; 0904-7107; 62756-136; 65372-1152; 55111-352; 55111-066; 71209-013; 55111-353; 65862-612; 75834-136; 72241-011; 33342-091; 53104-7571; 46708-064; 72241-013; 51991-796; 72241-012; 75834-133; 51991-793; 72241-014; 46708-065; 70518-3012; 46708-063
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C18H28N2O8
CAS Registry Number 129101-54-8
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T99799Not Available
DiarrhoeaCholinesteraseP06276T99799Not Available
DizzinessCholinesteraseP06276T99799Not Available
VomitingCholinesteraseP06276T99799Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac fibrillation02.03.02.021--Not Available
Psychotic disorder19.03.01.002--
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010--Not Available
Congenital joint malformation15.11.06.004; 03.11.06.004--Not Available
Cystitis noninfective20.03.02.001--
Application site hypersensitivity08.02.01.013; 12.07.01.014; 10.01.03.009--Not Available
Exfoliative rash23.03.07.006--Not Available
Breath sounds abnormal13.15.01.008--Not Available
Application site burn23.03.11.013; 08.02.01.038; 12.07.01.038--Not Available
Bronchial hyperreactivity22.03.01.016--Not Available
Anorectal discomfort07.03.03.003--Not Available
Acute kidney injury20.01.03.016--
Candida infection11.03.03.021--
Sinus node dysfunction02.03.03.017--
Anal incontinence17.05.01.021; 07.01.06.029--
Liver function test increased13.03.01.044--Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
The 15th Page    First    Pre   15    Total 15 Pages